PHPatricia Hall-Eidson

Patricia Hall-Eidson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Patricia Hall-Eidson has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Near point-of-care nucleic acid amplification tests (NPOC-NAATs) using respiratory specimens for detection of pulmonary tuberculosis

    by David J Horne, Jerry S Zifodya, Ermias Diro Ejara, Taylor D Coston, Adrienne E Shapiro, Mikashmi Kohli, Samuel G Schumacher, Patricia Hall-Eidson, Alexei Korobitsyn, Yemisi Takwoingi

  • Open Access

    Symptom-agnostic endpoints in tuberculosis vaccine efficacy trials

    by Morten Ruhwald, Alemnew F Dagnew, Gavin Churchyard, Adam Penn-Nicholson, Puneet Dewan, Alberto L Garcia-Basteiro, Emily B Wong, Willem A Hanekom, Mark Hatherill, Reinout van Crevel, et al.

  • Leveraging PEPFAR- and Global Fund–Supported Laboratory Network for Integrated Disease Testing: Lessons From Integrated HIV, Tuberculosis, and COVID-19 Testing in Nigeria

    by McPaul Okoye, Catherine Okoi, Nicole Espy, Nwando Mba, Celestina Obiekea, Anthony Ahumibe, Kingsley Madubuike, Nnaemeka Ndodo, Innocent Okoli, Kingsley Njoku, et al.

    The Nigeria Centre for Disease Control and Prevention, as part of the strategic approach to the COVID-19 outbreak response in Nigeria, coordinated the implementation of an integrated disease testing (IDT) strategy with support from multiple partners. This involved adaptation of existing US President's Emergency Plan for AIDS Relief (PEPFAR)– and Global Fund–supported molecular laboratory networks and integration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing into these. This enabled the country to provide large-scale testing and rapid return of results for SARS-CoV-2 from 2020 to 2022. IDT provided an opportunity for mainstreaming outbreak response into existing human immunodeficiency virus (HIV) and tuberculosis testing laboratories. Lessons learned from this have informed the adoption of IDT across the country laboratory network as an efficient approach to multiple disease testing and pandemic preparedness and response in Nigeria.


  • Open Access

    A global proficiency testing programme for Xpert® MTB/RIF using dried tube specimens, 2013–2015

    by Katherine Klein, Kyle DeGruy, Zilma Rey, Patricia Hall, Andrea Kim, Steve Gutreuter, Heather Alexander

    Background: Proficiency testing (PT) is an important quality assurance measure toward ensuring accurate and reliable diagnostic test results from clinical and public health laboratories. Despite the rapid expansion of the Xpert® MTB/RIF assay for the detection of tuberculosis in resource-limited settings (RLS), low-cost PT materials for Xpert MTB/RIF external quality assessment (EQA) are not widely available.Objective: We sought to determine whether a dried tube specimen (DTS)-based PT programme would be a feasible option to support Xpert MTB/RIF EQA in RLS.Methods: Between 2013 and 2015, the United States Centers for Disease Control and Prevention developed and conducted a voluntary EQA programme using DTS-based PT material. Eight rounds of PT, each comprising five DTS samples, were provided to enrolled testing sites. After each round, participant results were compared to expected results, scored as satisfactory or unsatisfactory, and sites were provided with performance reports.Results: Programme enrolment increased from 102 testing sites in seven countries to 441 testing sites in 14 countries over the course of three years. In each PT round, approximately 90% of participating sites demonstrated satisfactory performance. In seven of the 14 enrolled countries, the proportion of sites with a satisfactory score increased between the first round of participation and the most recent round of participation.Conclusion: This programme demonstrated that it is possible to implement an Xpert MTB/RIF PT programme for RLS using DTS, that substantial demand for Xpert MTB/RIF PT material exists in RLS, and that country performance can improve in a DTS-based PT programme.


  • Open Access

    Development of dried tube specimens for Xpert MTB/RIF proficiency testing

    by Kyle DeGruy, Katherine Klein, Zilma Rey, Patricia Hall, Andrea Kim, Heather Alexander

    Background: Proficiency testing (PT) is part of a comprehensive quality assurance programme, which is critical to ensuring patients receive accurate and reliable diagnostic testing. Implementation of the Cepheid Xpert® MTB/RIF assay to aid in the diagnosis of tuberculosis has expanded rapidly in recent years; however, PT material for Xpert MTB/RIF is not readily available in many resource-limited settings.Objective: To develop an accurate and precise PT material based on the dried tube specimen (DTS) method, using supplies and reagents available in most tuberculosis culture laboratories.Methods: Dried tube specimens were produced at the United States Centers for Disease Control and Prevention from 2013 to 2015 by inactivating liquid cultures of well-characterised mycobacterial strains. Ten percent of DTS produced were tested with Xpert MTB/RIF and evaluated for accuracy and precision.Results: Validation testing across eight rounds of PT demonstrated that DTS are highly accurate, achieving an average of 96.8% concordance with the Xpert MTB/RIF results from the original mycobacterial strains. Dried tube specimen testing was also precise, with cycle threshold standard deviations below two cycles when inherent test cartridge variability was low.Conclusion: Dried tube specimens can be produced using equipment already present in tuberculosis culture laboratories, making Xpert MTB/RIF PT scale-up more feasible in resource-limited settings. Use of DTS may fill the gap in tuberculosis laboratory access to external quality assessment, which is an essential component of a comprehensive continuous quality improvement programme.